Skip to main content

Thermo Fisher Scientific stock price and financials

  • TMO · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$700.22+0.11%Close 13 Nov 2026
EV / EBITDA
25.48
Beta · 1 year
0.69
Return · 1 year
+19.1%
52-week range$435.27 — $727.56

Share price close 16 Nov 2026

+0.0%1 monthHigh $721.63Low $673.82
$660$680$700$720$740Q3 FY2026 report filed 30 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+58.9%6 monthsHigh $721.63Low $442.00
$400$500$600$700$800Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+20.2%year to dateHigh $721.63Low $438.34
$400$500$600$700$800Q4 FY2025 report filed 26 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+20.4%1 yearHigh $721.63Low $438.34
$400$500$600$700$800Q4 FY2025 report filed 26 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+48.0%3 yearsHigh $721.63Low $390.26
$300$400$500$600$700$800Q4 FY2023 report filed 22 Feb 2024Q1 FY2024 report filed 3 May 2024Q2 FY2024 report filed 2 Aug 2024Q3 FY2024 report filed 1 Nov 2024Q4 FY2024 report filed 20 Feb 2025Q1 FY2025 report filed 2 May 2025Q2 FY2025 report filed 1 Aug 2025Q3 FY2025 report filed 31 Oct 2025Q4 FY2025 report filed 26 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+378%10 yearsHigh $721.63Low $141.10
$0$200$400$600$800Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Thermo Fisher Scientific reported revenue of $44.6 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 3.9% from fiscal 2024. Net income was $6.70 billion and diluted earnings per share $17.74.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 26 Sep 2026), revenue was $12.1 billion, up 9.1% from a year earlier.

Figures from Thermo Fisher Scientific's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Revenue FY2025
$44.56B+3.9%
Net income
$6.70B+5.8%
Diluted EPS
$17.74+7.3%
Gross margin
40.9%−0.4 pts
Free cash flow
$6.29B−13.4%
Net debt
$30.75B+13.0%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$10B$20B$30B$40B$50BRevenue, FY16: $18.27BNet income, FY16: $2.02BFY16Revenue, FY17: $20.92BNet income, FY17: $2.23BFY17Revenue, FY18: $24.36BNet income, FY18: $2.94BFY18Revenue, FY19: $25.54BNet income, FY19: $3.7BFY19Revenue, FY20: $32.22BNet income, FY20: $6.38BFY20Revenue, FY21: $39.21BNet income, FY21: $7.72BFY21Revenue, FY22: $44.91BNet income, FY22: $6.95BFY22Revenue, FY23: $42.86BNet income, FY23: $6BFY23Revenue, FY24: $42.88BNet income, FY24: $6.33BFY24Revenue, FY25: $44.56BNet income, FY25: $6.7BFY25

Latest quarter · Q3 FY2026 to 26 Sep 2026, filed 30 Oct 2026 · Full results →

Revenue
$12.14B+9.1% on a year
Gross margin
42.3%+1.1 pts on a year
Operating income
$2.26B+16.6% on a year
Net income
$1.72B+6.5% on a year
Diluted EPS
$4.64+8.7% on a year
Free cash flow
$2.11B+15.1% on a year

Comparable companies All of Health Care →

Thermo Fisher Scientific beside the other S&P 500 members in Life Sciences Tools & Services, by market value.

Thermo Fisher Scientific and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Thermo Fisher ScientificTMO—+0.1%+19.1%———
Danaher CorporationDHR$163.0B+0.4%+6.2%+5.5%16.9%37.6
Agilent TechnologiesA$48.72B+0.5%+14.8%+8.6%19.5%33.8
IQVIAIQV$43.52B−2.2%+20.0%+8.8%8.1%31.2
IlluminaILMN$30.43B−4.2%+65.3%+5.8%19.7%34.0
Charles River LaboratoriesCRL$16.06B−0.8%+97.1%−1.2%1.0%399.6
Bio-TechneTECH—−0.1%+18.6%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%20%40%60%40.9%17.4%15.0%FY16FY19FY22FY25

Thermo Fisher Scientific revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Thermo Fisher Scientific revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Laboratory Products and Biopharma Services$14.86B$22.51B+51.5%$23.04B+2.4%$23.16B+0.5%$23.98B+3.6%
Life Sciences Solutions$15.63B$13.53B−13.4%$9.98B−26.3%$9.63B−3.5%$10.37B+7.7%
Analytical Instruments$6.07B$6.62B+9.1%$7.26B+9.6%$7.46B+2.8%$7.55B+1.2%
Specialty Diagnostics$5.66B$4.76B−15.8%$4.41B−7.5%$4.51B+2.4%$4.68B+3.6%
Total revenue$39.21B$44.91B$42.86B$42.88B$44.56B

By product

Thermo Fisher Scientific revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Consumables$22.61B$20.62B−8.8%$17.60B−14.7%$17.59B−0.1%$18.66B+6.1%
Service revenues$8.85B$16.37B+84.9%$17.61B+7.6%$17.84B+1.3%$18.59B+4.2%
Instruments$7.75B$7.92B+2.2%$7.65B−3.5%$7.45B−2.6%$7.30B−1.9%
Total revenue$39.21B$44.91B$42.86B$42.88B$44.56B

By region

Thermo Fisher Scientific revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
North America$19.66B$24.59B+25.1%$22.76B−7.4%$22.50B−1.1%$23.03B+2.4%
Europe$11.13B$10.76B−3.3%$10.74B−0.2%$10.86B+1.1%$11.83B+8.9%
Asia-Pacific$7.22B$8.12B+12.4%$7.87B−3.0%$7.96B+1.1%$8.10B+1.8%
Other regions$1.20B$1.44B+20.3%$1.48B+2.4%$1.56B+5.5%$1.60B+2.3%
Total revenue$39.21B$44.91B$42.86B$42.88B$44.56B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Thermo Fisher Scientific income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$18.27B$20.92B$24.36B$25.54B$32.22B$39.21B$44.91B$42.86B$42.88B$44.56B
Revenue growth+7.7%+14.5%+16.4%+4.9%+26.1%+21.7%+14.5%−4.6%+0.1%+3.9%
Gross profit$10.06B$11.94B$10.86B$11.33B$16.00B$19.64B$18.97B$17.10B$17.70B$18.24B
Operating income$2.46B$2.96B$3.78B$4.59B$7.79B$10.03B$8.39B$6.86B$7.34B$7.75B
Net income$2.02B$2.23B$2.94B$3.70B$6.38B$7.72B$6.95B$6.00B$6.33B$6.70B
Diluted EPS$5.09$5.59$7.24$9.17$15.96$19.46$17.63$15.45$16.53$17.74
Gross margin55.1%57.1%44.6%44.4%49.7%50.1%42.2%39.9%41.3%40.9%
Operating margin13.5%14.2%15.5%18.0%24.2%25.6%18.7%16.0%17.1%17.4%
Net margin11.1%10.6%12.1%14.5%19.8%19.7%15.5%14.0%14.8%15.0%

Cash flow

Thermo Fisher Scientific cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$3.26B$4.00B$4.54B$4.97B$8.29B$9.31B$9.15B$8.41B$8.67B$7.82B
Capital expenditure$444.0M$508.0M$758.0M$926.0M$1.47B$2.52B$2.24B$1.48B$1.40B$1.52B
Free cash flow$2.81B$3.50B$3.79B$4.05B$6.82B$6.79B$6.91B$6.93B$7.27B$6.29B

Balance sheet and shares

Thermo Fisher Scientific balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$786.0M$1.33B$2.10B$2.40B$10.32B$4.48B$8.52B$8.08B$4.01B$9.85B
Total debt$16.63B$21.01B$18.99B$18.49B$22.55B$36.34B$36.07B$36.42B$32.78B$40.85B
Shareholders' equity$21.54B$25.41B$27.59B$29.68B$34.51B$40.79B$43.98B$46.73B$49.58B$53.41B
Diluted shares397M398M406M403M399M397M394M388M383M378M
Dividends per share$0.60$0.60$0.68$0.76$0.88$1.04$1.20$1.40$1.56$1.72

Quarterly figures

The last eight fiscal quarters, the latest ending 26 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Thermo Fisher Scientific quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$11.39B$10.36B$10.86B$11.12B$12.21B$11.01B$11.99B$12.14B
Revenue, year on year+4.7%+0.2%+3.0%+4.9%+7.2%+6.2%+10.5%+9.1%
Gross margin42.3%40.9%40.6%41.2%41.0%40.3%40.7%42.3%
Operating income$2.02B$1.72B$1.83B$1.94B$2.25B$1.86B$2.09B$2.26B
Net income$1.83B$1.51B$1.62B$1.62B$1.96B$1.65B$1.74B$1.72B
Diluted EPS$4.78$3.98$4.28$4.27$5.21$4.43$4.68$4.64
Free cash flow$2.81B$361.0M$1.10B$1.83B$2.99B$816.0M$1.68B$2.11B

Operating KPIs

The operating figures Thermo Fisher Scientific reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Thermo Fisher Scientific operating KPIs
KPILatestPeriodChange on a yearRecent periods
Organic revenue (change on a year)6%quarter to 26 Sep 2026up 3.0 points
Remaining performance obligations$29.9Bat 26 Sep 2026up 12.9%
Product revenues$6.8Bquarter to 26 Sep 2026up 4.1%
Service revenues$5.4Bquarter to 26 Sep 2026up 16.2%
Consumables revenue$4.9Bquarter to 26 Sep 2026up 4.1%
Instruments revenue$1.9Bquarter to 26 Sep 2026up 4.0%
Clinical research revenue$2.4Bquarter to 26 Sep 2026up 21.1%
Research and safety market channel revenue$2.0Bquarter to 26 Sep 2026up 9.1%
Pharma services revenue$2.0Bquarter to 26 Sep 2026up 17.8%
Biosciences revenue$1.0Bquarter to 26 Sep 2026up 0.2%
BioProduction revenue$896.0Mquarter to 26 Sep 2026up 9.7%
Chromatography and mass spectrometry revenue$859.0Mquarter to 26 Sep 2026up 2.1%
Electron microscopy revenue$827.0Mquarter to 26 Sep 2026up 13.0%
Genetic sciences revenue$702.0Mquarter to 26 Sep 2026down 2.5%
Laboratory products revenue$603.0Mquarter to 26 Sep 2026up 1.5%
Healthcare market channel revenue$454.0Mquarter to 26 Sep 2026up 2.3%
Chemical analysis revenue$316.0Mquarter to 26 Sep 2026down 1.2%
Clinical diagnostics revenue$269.0Mquarter to 26 Sep 2026down 4.9%
ImmunoDiagnostics revenue$232.0Mquarter to 26 Sep 2026up 0.9%
Transplant diagnostics revenue$131.0Mquarter to 26 Sep 2026up 4.8%
Microbiology revenue$70.0Mquarter to 26 Sep 2026down 56.8%
Laboratory Products and Biopharma Services revenue$6.9Bquarter to 26 Sep 2026up 15.0%
Life Sciences Solutions revenue$2.7Bquarter to 26 Sep 2026up 5.1%
Analytical Instruments revenue$2.0Bquarter to 26 Sep 2026up 5.8%
Specialty Diagnostics revenue$1.1Bquarter to 26 Sep 2026down 6.5%
North America revenue$6.3Bquarter to 26 Sep 2026up 10.1%
Europe revenue$3.2Bquarter to 26 Sep 2026up 6.5%
Asia-Pacific revenue$2.2Bquarter to 26 Sep 2026up 11.3%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Thermo Fisher Scientific's revenue in fiscal 2025?

$44.6 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Thermo Fisher Scientific's net income in fiscal 2025?

$6.70 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Thermo Fisher Scientific's diluted earnings per share in fiscal 2025?

$17.74 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Thermo Fisher Scientific's gross margin?

40.9% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Thermo Fisher Scientific's operating margin?

17.4% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Thermo Fisher Scientific generate in fiscal 2025?

$6.29 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Thermo Fisher Scientific's revenue come from?

In fiscal 2025, by product: Consumables $18.66B (42%), Service revenues $18.59B (42%), Instruments $7.30B (16%), out of $44.56B in all, as stated in its annual report.

In the terminal

Twenty years of Thermo Fisher Scientific's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans